Treatment Selection According to Skin Reaction to Cetuximab

Trial Title: Treatment Selection According to Skin Reaction to Cetuximab

NCT ID: NCT01472653

Condition: Head and Neck Cancer

Conditions: Official terms:
Head and Neck Neoplasms
Cetuximab

Conditions: Keywords:
Head and neck Cancer
Radiochemotherapy
Radioimmunotherapy
Skin rush
locoregional control
Survival
Toxicity

Study type: Interventional

Study phase: Phase 2

Overall status: Unknown status

Study design:

Allocation: N/A

Intervention model: Single Group Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: cisplatin
Description: cisplatin 30 mg/m2/week I.V. during radiotherapy

Intervention type: Radiation
Intervention name: radiotherapy
Description: 3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks

Intervention type: Drug
Intervention name: cetuximab
Description: cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy

Other name: Erbitux

Summary: The therapy of patients with locally advanced head and neck cancer will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e. either with radioimmunotherapy (radiotherapy and Cetuximab) or radiochemotherapy (radiotherapy and Cisplatin.

Detailed description: Background: According to literature, the treatment results in irradiated patients who develop intensive skin reaction after concomitant Cetuximab administration appear improved as compared to the results of standard combination of radiotherapy and Cisplatin. In other patients, no beneficial effect of Cetuximab is expected and the therapy with Cisplatin (concomitantly with irradiation) is more effective in this group. In this proposed single-institution non-randomized phase II study on patients with locally advanced squamous cell carcinoma of the head and neck, the therapy will be adjusted to the grade of skin rush as recorded after the first two cycles of Cetuximab and Cisplatin, i.e. either with radioimmunotherapy (radiotherapy and Cetuximab) or radiochemotherapy (radiotherapy and Cisplatin). Methods: In the patients with inoperable tumors, induction chemotherapy (Docetaxel 75 mg/m2, Cisplatin 75 mg/m2, 5-Fluorouracil 750 mg/m2 in continuous infusion days 1-5; repeated every 21 days for 4 cycles) will be administered. In the week before the first fraction of radiotherapy, all patients will receive a loading dose of Cetuximab (400 mg/m2) and combination of Cetuximab (250 mg/m2) and Cisplatin (30 mg/m2) during the first week of irradiation. After multidisciplinary assessment of the grade of skin rush, conducted at the end of the second week of irradiation, the patients will be grouped as follows: arm A - skin rush of CTCAE v3.0 grade <2 will proceed with radiochemotherapy with Cisplatin; arm B - skin rush of CTCAE v3.0 grade >=2 will proceed with radioimmunotherapy with Cetuximab. The planned number of patients included in the study is 120 (arm A - 50, arm B - 70) and recruitment period is 3 years. The primary objective of the study is to determine radiologically the complete response rate 12-14 weeks after therapy. The secondary objectives are locoregional control, progression-free survival and overall survival at 2 years after therapy, acute and late toxicity. Expected results: The expected complete response rate in patients treated with radiochemotherapy and those treated with radioimmunotherapy is 50% and 75%, respectively. We also expect the difference in an absolute survival gain between the groups to be 25%.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Squamous cell carcinoma, histologically proven (with HPV-status determined in patients with oropharyngeal primary) - Tumour site: oral cavity, oropharynx, hypopharynx or larynx. - Locally and/or regionally operable and inoperable tumors (UICC TNM stages III, IVa or IVb), without distant metastases (M0-stage) - Male or female ≥18 years of age - Expected survival >6 months - WHO performance status 0-2 - Laboratory parameters: hemoglobin ≥100 g/L; leukocyte count > 3.5x109/L, absolute neutrophil count ≥ 1.5x109/L; platelet count > 100x109/L; total bilirubin < 1.25x upper normal limit; transaminases (ALT, AST) < 5x upper normal limit; creatinine clearance (ECC) ≥ 60 ml/minute; - Presence of at least one bidimensionally measurable index lesion - Effective contraception for both male and female subjects if risk of conception exists - Signed written informed consent Exclusion Criteria: - Other previous malignancy within 5 years, with exception of a history of a previously adequately treated basal cell carcinoma of the skin or pre- invasive carcinoma of the cervix - Chemotherapy ineligibility: unstable cardiopulmonary, renal and liver disease likely to compromise the safe delivery of I.V. infusion (chemotherapy); haematologic diseases; clinically evident hearing impairment; pre-existing motor or sensory neurotoxicity grade ≥ 2 according to the CTCAE v3.0; previous administration of Cetuximab or Cisplatin; - Active, uncontrolled infection - Medical or psychological condition which in the opinion of the investigator precludes the safe administration of the planned radiotherapy or systemic therapy - Known drug abuse or severe alcohol abuse - Pregnancy or breast feeding

Gender: All

Minimum age: 18 Years

Maximum age: 70 Years

Healthy volunteers: No

Locations:

Facility:
Name: Institute of Oncology Ljubljana

Address:
City: Ljubljana
Zip: SI-1000
Country: Slovenia

Status: Recruiting

Contact:
Last name: Primož Strojan, Prof.
Email: pstrojan@onko-i.si

Investigator:
Last name: Marta Dremelj, MD, MSc
Email: Sub-Investigator

Investigator:
Last name: Igor Fajdiga, MD, PhD
Email: Sub-Investigator

Investigator:
Last name: Cvetka Kuhar Grašič, MD, PhD
Email: Sub-Investigator

Investigator:
Last name: Jančar Boris, MD, MSc
Email: Sub-Investigator

Investigator:
Last name: Simona Jereb, MD
Email: Sub-Investigator

Investigator:
Last name: Katarina Karner, MD, MSc
Email: Sub-Investigator

Investigator:
Last name: Barbara Žumer, MD
Email: Sub-Investigator

Start date: December 2011

Completion date: December 2016

Lead sponsor:
Agency: Institute of Oncology Ljubljana
Agency class: Other

Source: Institute of Oncology Ljubljana

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01472653